EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes

Randomisierter Vergleich intravenöser und subkutaner Wege der GLP-1-Gabe zur Senkung der Plasmaglukose bei hyperglykämischen Personen mit Typ-2-Diabetes

Daniel R Quast iD, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Karen L Jones iD, Michael Horowitz, Juris J Meier iD, Tongzhi Wu iD, Christopher K Rayner iD, Michael A Nauck iD

Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3897-3905

DOI: 10.1111/dom.15736 ↗

Auf einen Blick

Bei 10 nüchternen, hyperglykämischen Personen mit Typ-2-Diabetes senkte intravenöses GLP-1 die Plasmaglukose stärker als subkutanes GLP-1. Auch die GLP-1-Exposition war intravenös höher.

Fragestellung

Vergleicht die subkutane mit der intravenösen GLP-1-Gabe bei hyperglykämischen Personen mit Typ-2-Diabetes die Senkung der Plasmaglukose?

Methode

Doppelblinde, randomisierte Crossover-Studie bei 10 nüchternen Personen; 8-stündige Messung von Glukose, GLP-1, Insulin, C-Peptid, Glukagon und gastrointestinalen Symptomen.

Ergebnisse

Plasmaglukose sank mit intravenösem GLP-1 um ~8,0 mmol/L [144 mg/dL] und mit subkutanem GLP-1 um ~5,6 mmol/L [100 mg/dL] (p < 0,001). Gesamt- und intaktes GLP-1 stiegen intravenös stärker an.

Schlussfolgerung der Autor:innen

Subkutanes GLP-1 war zur Senkung der Nüchternplasmaglukose deutlich weniger wirksam als intravenöses GLP-1 und zeigte geringere Insulinstimulation, geringere Glukagonsuppression und geringere Bioverfügbarkeit.

Kernaussagen

  • Intravenöses GLP-1 senkte die Plasmaglukose stärker als subkutanes GLP-1
  • Gesamt- und intaktes GLP-1 stiegen intravenös stärker an
  • Gastrointestinale Symptome unterschieden sich nicht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024-07. Verfasst von Daniel R Quast und 10 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelai…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Cross-Over Studies, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Royal Adelaide Hospital Research Committee Clinical Project Grant.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To perform a direct, double‐blind, randomised, crossover comparison of subcutaneous and intravenous glucagon‐like peptide‐1 (GLP‐1) in hyperglycaemic subjects with type 2 diabetes naïve to GLP‐1‐based therapy. Materials and Methods Ten fasted, hyperglycaemic subjects (1 female, age 63 ± 10 years [mean ± SD], glycated haemoglobin 73.5 ± 22.0 mmol/mol [8.9% ± 2.0%], both mean ± SD) received subcutaneous GLP‐1 and intravenous saline, or intravenous GLP‐1 and subcutaneous saline. Infusion rates were doubled every 120 min (1.2, 2.4, 4.8 and 9.6 pmol·kg −1 ·min −1 for subcutaneous, and 0.3, 0.6, 1.2 and 2.4 pmol·kg −1 ·min −1 for intravenous). Plasma glucose, total and intact GLP‐1, insulin, C‐peptide, glucagon and gastrointestinal symptoms were evaluated over 8 h. The results are presented as mean ± SEM.

Results

Plasma glucose decreased more with intravenous (by ~8.0 mmol/L [144 mg/dL]) than subcutaneous GLP‐1 (by ~5.6 mmol/L [100 mg/dL]; p < 0.001). Plasma GLP‐1 increased dose‐dependently, but more with intravenous than subcutaneous for both total (∆ max 154.2 ± 3.9 pmol/L vs. 85.1 ± 3.8 pmol/L; p < 0.001), and intact GLP‐1 (∆ max 44.2 ± 2.2 pmol/L vs. 12.8 ± 2.2 pmol/L; p < 0.001). Total and intact GLP‐1 clearance was higher for subcutaneous than intravenous GLP‐1 ( p < 0.001 and p = 0.002, respectively). The increase in insulin secretion was greater, and glucagon was suppressed more with intravenous GLP‐1 ( p < 0.05 each). Gastrointestinal symptoms did not differ ( p > 0.05 each).

Conclusions

Subcutaneous GLP‐1 administration is much less efficient than intravenous GLP‐1 in lowering fasting plasma glucose, with less stimulation of insulin and suppression of glucagon, and much less bioavailability, even at fourfold higher infusion rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Cross-Over StudiesBlood GlucoseHyperglycemiaHypoglycemic AgentsHumansFemaleMiddle AgedMaleDouble-Blind MethodAgedInjections, SubcutaneousInsulinInfusions, IntravenousGlycated HemoglobinGlucagonC-Peptide

Stichwörter der Autor:innen

GLP‐1clinical physiologyeffectivenessincretin physiologyrandomised trialtype 2 diabetes

Substanzen

Glucagon-Like Peptide 1Blood GlucoseHypoglycemic AgentsInsulinGlycated HemoglobinGlucagonC-Peptide

Autor:innen und Institutionen

  • Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.
  • Diabetes, Endocrinology and Metabolism Section, Department of Internal Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
  • Department of Internal Medicine, Augusta-Hospital, Bochum, Germany.
  • Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia.

ORCID-Profile: Daniel R Quast, Karen L Jones, Juris J Meier, Tongzhi Wu, Christopher K Rayner, Michael A Nauck

Förderung

  • National Health and Medical Research Council
  • Royal Adelaide Hospital Research Committee Clinical Project Grant

Zitieren

APA

Quast, D. R., Lancaster, D., Xie, C., Bound, M. J., Grivell, J., Jones, K. L., Horowitz, M., Meier, J. J., Wu, T., Rayner, C. K., & Nauck, M. A. (2024). Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 26(9), 3897-3905. https://doi.org/10.1111/dom.15736

Vancouver

Quast DR, Lancaster D, Xie C, Bound MJ, Grivell J, Jones KL, et al. Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024;26(9):3897-3905. doi:10.1111/dom.15736

BibTeX
@article{Quast2024,
  author = {Quast, Daniel R and Lancaster, Dara and Xie, Cong and Bound, Michelle J and Grivell, Jacqueline and Jones, Karen L and Horowitz, Michael and Meier, Juris J and Wu, Tongzhi and Rayner, Christopher K and Nauck, Michael A},
  title = {Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {3897--3905},
  doi = {10.1111/dom.15736}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche